Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Gestational Hypertension, Cardiovascular...
Phase NA
Enrollment 140
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

To compare the cardiovascular profile of pre-conceptional women at risk for developing Gestational Hypertensive Disorders in subsequent pregnancy before and after physical activity.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: supervised infrared exercise group — Participants of the intervention group will be asked to perform 1-3 exercise sessions per week at the Infraligne center of Genk, Hasselt or Maasmechelen for a total duration of 12 weeks. During the exercise session, the participant is assigned to an individual 'sport cabin' in which they are standardly exposed to infrared light.
  • Other: supervised non-infrared exercise group — Participants of the intervention group will be asked to perform 1-3 exercise sessions per week at the Infraligne center of Genk, Hasselt or Maasmechelen for a total duration of 12 weeks. Participants assigned to the supervised non-infrared exercise group will exercise in the sport-cabin with the infrared light turned off.
  • Other: Control group — Participants of the control group are advised to perform moderate intensity aerobic exercise at least 3 days per week for an average of 30-50 minutes per session and a total duration of 12 weeks.

Primary Outcomes

  • Change in cardiac output level from Baseline at week 12 visit (Baseline and week 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-05-15
Completion: 2025-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hasselt University
Principal Investigators:
  • Dorien Lanssens (PRINCIPAL_INVESTIGATOR) - UHasselt
Contact Information
Study Contact:
Pauline Dreesen
089212030
pauline.dreesen@uhasselt.be
Marleen Missotten
011268502
marleen.missotten@uhasselt.be
Hasselt University
Interventions
  • Other: supervised infrared exercise group — Participants of the intervention group will be asked to perform 1-3 exercise sessions per week at the Infraligne center of Genk, Hasselt or Maasmechelen for a total duration of 12 weeks. During the exercise session, the participant is assigned to an individual 'sport cabin' in which they are standardly exposed to infrared light.
  • Other: supervised non-infrared exercise group — Participants of the intervention group will be asked to perform 1-3 exercise sessions per week at the Infraligne center of Genk, Hasselt or Maasmechelen for a total duration of 12 weeks. Participants assigned to the supervised non-infrared exercise group will exercise in the sport-cabin with the infrared light turned off.
  • Other: Control group — Participants of the control group are advised to perform moderate intensity aerobic exercise at least 3 days per week for an average of 30-50 minutes per session and a total duration of 12 weeks.
Study Locations (1 sites)
Hasselt University, Diepenbeek, Limburg 3590 Belgium
Eligibility Criteria
Inclusion Criteria: * Women at risk for the development of GHD in subsequent pregnancy based on the presence of at least one of the following risk factors: * high body mass index (BMI\>30 kg/m²) * a family history of PE (mother, sister) * in the need of assisted reproduction techniques in a previous or subsequent pregnancy * maternal comorbidities: prior PE, diabetes mellitus, chronic hypertension, chronic kidney disease or antiphospholipid syndrome * Non-pregnant (as confirmed by a negative pregnancy urine dipstick test) * Age ≥ 18 years * Being able to understand the Dutch language Exclusion Criteria: Participants eligible for this study must not meet any of the following criteria: * Pregnant at inclusion * Not being able to exercise according to physician's decision * Suffering from underlying diseases that can affect the CV profile such as oncological diseases coronary heart disease, aortic disease, peripheral arterial disease * Participating in another clinical study that may alter the results of this study
Conditions Preeclampsia, Pregnancy
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. There is a lack of effective therapeutics for prevention or treatment. Our previous ex vivo work demonstrated that mitochondrial-antioxidants can reverse placental microvascular damage. Therefore, this study will evaluate whether MitoQ (Mitoquinol Mesylate, a mitochondrial-antioxidant) has the potential to restore vasodilation, improve placental function, and therefore promote pregnancy prolongation in patients with preeclampsia. This evaluation of clinical data, patient samples, and vascular function studies in patients with preeclampsia could translate into a viable therapeutic option.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: Mitoquinol Mesylate — Patients randomized to the intervention will receive 10mg of Mitoquinol Mesylate daily from enrollment until delivery.
  • Other: Placebo — Patients randomized to the placebo groups will take 1 placebo capsule daily until delivery.

Primary Outcomes

  • Brachial Artery Flow Mediated Dilation (FMD) (1-2 times per week from enrollment until delivery, up to 10 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-18
Completion: 2027-09-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical College of Wisconsin
Collaborators: Bill and Melinda Gates Foundation
Principal Investigators:
  • Jennifer J McIntosh, D.O., (PRINCIPAL_INVESTIGATOR) - Medical College of Wisconsin
Contact Information
Study Contact:
Jennifer McIntosh, D.O., M.S.
14148059019
jmcintosh@mcw.edu
Jennifer McIntosh
4148059019
jmcintosh@mcw.edu
Froedtert & the Medical College of Wisconsin
Interventions
  • Dietary Supplement: Mitoquinol Mesylate — Patients randomized to the intervention will receive 10mg of Mitoquinol Mesylate daily from enrollment until delivery.
  • Other: Placebo — Patients randomized to the placebo groups will take 1 placebo capsule daily until delivery.
Study Locations (1 sites)
Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin 53226 United States
Eligibility Criteria
Inclusion Criteria: * Inpatient Cohort * pregnant patients with a clinical diagnosis of preeclampsia with severe features * gestational age between 23+0 and 32+0 weeks' gestation * singleton pregnancy * age 18-50 years old * No indication for immediate delivery (e.g. the patient and their physician team have planned expectant management of preeclampsia with severe features * Able to consent and follow a 2-step commend * English speaking * Outpatient Cohort * Pregnant patients with a clinical diagnosis of preeclampsia without severe features * gestational age between 23+0 and 34+0 weeks' gestation * singleton pregnancy * age 18-50 years old * No indication for immediate delivery * Planned outpatient management of preeclampsia * Able to consent and follow a 2-step commend * English speaking Exclusion Criteria: * • Unable to stand from chair without physical assistance from another person (able to use assistive device). * History of blood clots in the extremities or any condition in which compression of the thigh or transient ischemia is contraindicated (i.e., wounds in the leg). * Chronic lasting symptoms (\> 6 months) of severe COVID-19 (i.e., hospitalization) * History of head trauma or concussion within the past 6 months * Comorbid neurological disorder * Peripheral vascular disease * Diagnosed myocardial infarction or arrhythmia in the previous year * Resting SBP ≥180 mmHg or DBP ≥ 100 mmHg * Other significant medical condition likely to influence study or jeopardize safety as assessed by the Primary Investigator
Conditions Supine Hypertension, Autonomic Failure
Phase NA
Enrollment 12
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe and complicates the treatment of orthostatic hypotension. The purpose of this study is to assess whether continuous positive airway pressure (CPAP) decreases blood pressure in autonomic failure patients with supine hypertension.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: continuous positive airway pressure (CPAP) — Continuous positive airway pressure(CPAP) will be applied during the night starting from 20:00. CPAP level will be determined during an acute CPAP trial.
  • Drug: Placebo — Placebo pill or patch. Single dose

Primary Outcomes

  • Supine Systolic Blood Pressure (12 hours)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2017-09-21
Completion: 2026-12-21
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 12 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vanderbilt University Medical Center
Principal Investigators:
  • Italo Biaggioni, MD (PRINCIPAL_INVESTIGATOR) - Vanderbilt University Medical Center
Contact Information
Study Contact:
Bonnie K Black, RN
615-343-6862
autonomics@vumc.org
Luis E Okamoto, MD
(615) 936-6119
autonomics@vumc.org
Emily C Smith, RN
615-875-1516
autonomics@vumc.org
Autonomic Dysfunction Center/ Vanderbilt University Medical Center
Interventions
  • Device: continuous positive airway pressure (CPAP) — Continuous positive airway pressure(CPAP) will be applied during the night starting from 20:00. CPAP level will be determined during an acute CPAP trial.
  • Drug: Placebo — Placebo pill or patch. Single dose
Study Locations (1 sites)
Autonomic Dysfunction Center/ Vanderbilt University Medical Center, Nashville, Tennessee 37232 United States
Eligibility Criteria
Inclusion Criteria: * Patients with autonomic failure and with supine hypertension from all races Exclusion Criteria: * All medical students * Pregnant women * High-risk patients (e.g. heart failure, symptomatic coronary artery disease, liver impairment, history of stroke or myocardial infarction) * History of serious allergies or asthma.
Conditions Intrahepatic Cholangiocarcinoma (Icc)
Phase PHASE2
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

This study was a randomized controlled trial to evaluate the efficacy and safety of toripalimab combined with GemCis (gemcitabine and cisplatin) as preoperative neoadjuvant therapy for resectable ICC at high risk of recurrence.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Teripalimab — 240mg intravenous injection, D1, q3w, for 9 weeks (3 cycles)
  • Drug: Gemcitabine + Cisplatin — Gemcitabine 1000mg/m2 + cisplatin 25mg/m2, D1\&D8, q3w, for 9 weeks (3 cycles)
  • Procedure: Surgery — Radical resection

Primary Outcomes

  • 1-year recurrence-free survival rate (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-11-12
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital
Contact Information
Study Contact:
Qiang Wu
+86-13821413914
wuqiangtianjin@hotmail.com
Interventions
  • Drug: Teripalimab — 240mg intravenous injection, D1, q3w, for 9 weeks (3 cycles)
  • Drug: Gemcitabine + Cisplatin — Gemcitabine 1000mg/m2 + cisplatin 25mg/m2, D1\&D8, q3w, for 9 weeks (3 cycles)
  • Procedure: Surgery — Radical resection
Study Locations (1 sites)
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin Municipality 300060 China
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18, male or female; 2. Pathological diagnosis confirmed intrahepatic cholangiocarcinoma, which could be resected surgically; One of the following conditions shall be met: 2.1 Single tumor, diameter greater than 5cm (T1b) 2.2 Single tumor with vascular invasion (T2), multiple tumors ≤ 3 2.3 Tumor penetrating visceral peritoneum (T3) or directly invading surrounding organs (T4) 2.4 Suspicious lymph node metastasis in Zone 8, 12 or 13 3. Can not received systemic treatment before participating in the study; 4. ECOG PS score 0-1; 5. The main organs function normally, and there is no serious blood, heart, lung, liver, kidney, bone marrow and other functional abnormalities and immune deficiency diseases. 6. Laboratory inspection shall meet the following requirements: Women of childbearing age must have a negative pregnancy test (serum or urine) within 14 days before enrollment, and voluntarily use appropriate methods of contraception during the observation period and within 8 weeks after the last administration of the study drug; For men, they should be surgically sterilized or agree to use appropriate methods of contraception during the observation period and within 8 weeks after the last administration of the study drug. 7. The patient voluntarily participated and signed the informed consent form; 8. It is expected that the compliance is good, and the efficacy and adverse reactions can be followed up according to the requirements of the scheme. Exclusion Criteria: 1. Patients who received PD-1, PD-L1, PD-L2, CTLA-4 before enrollment, or directly received another stimulatory or co inhibitory T cell receptor (such as CTLA-4, 0X40, CD137); 2. Any other research drugs within 4 weeks before enrollment; 3. Any active autoimmune disease or history of autoimmune disease (such as interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism after hormone replacement therapy); 4. Congenital or acquired immune function defects, such as human immunodeficiency virus (HIV) infection; 5. Uncontrollable clinical cardiac symptoms or diseases, such as NYHA II and above heart failure unstable angina pectoris, myocardial infarction within one year, and clinically significant supraventricular or ventricular arrhythmia requiring clinical intervention; 6. Severe infection (such as intravenous drip of antibiotics, antifungal or antiviral drugs) occurred within 4 weeks before the first drug administration, or fever of unknown cause\>38.5 ° C occurred during screening/before the first drug administration; 7. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; 8. Live attenuated vaccine shall be inoculated within 4 weeks before the first administration or planned during the study period; 9. Suffered from or accompanied by other system malignant tumors in the last 5 years (except cured skin basal cell carcinoma, cervical carcinoma in situ and ovarian cancer); 10. Allergic to any test drug; 11. Pregnant and lactating women, fertile subjects are unwilling to take effective contraceptive measures; 12. Uncontrollable psychosis; 13. Other situations that the researcher thinks are not suitable for inclusion. If the patient has central nervous system metastasis, has serious laboratory examination abnormalities, and is accompanied by family or social factors, it will affect the safety of the subject, or the collection of data and samples.
Conditions Primary Angle-closure Glaucoma
Phase NA
Enrollment 68
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

This prospective randomized controlled trial, conducted by the Ophthalmology Department of Peking University People's Hospital, aims to compare the intraocular pressure (IOP)-lowering efficacy and safety of two surgical regimens-phacoemulsification with intraocular lens implantation plus goniosynechialysis (PEI-GSL) and PEI-GSL combined with Kahook Dual Blade (KDB) ab interno goniotomy (PEI-GSL-KDB)-in 68 patients (34 eyes per group) with chronic primary angle-closure glaucoma (PACG) complicated by age-related cataract. All surgeries are performed by senior glaucoma specialists, with a 1-year follow-up for outcomes assessment. The primary outcome is the 12-month IOP control success rate (IOP ≤21 mmHg with a ≥20% reduction from baseline, with or without topical hypotensive medications), and secondary outcomes include intra- and post-operative complications and changes in peripheral anterior synechiae (PAS). Statistical analyses will use t-tests, chi-square tests, etc., with P\<0.05 considered statistically significant. The study is scheduled from January 2024 to December 2025, and preliminary research has confirmed the safety and efficacy of combined glaucoma-cataract surgeries, laying a solid foundation for this trial.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Kahook Dual Blade (KDB) goniotomy — he Kahook Dual Blade (KDB) is an ab interno device engineered to precisely excise a strip of diseased TM and the inner wall of Schlemm's canal.
  • Device: phacoemulsification with intraocular lens implantation combined with goniosynechialysis — patients underwent standard phacoemulsification with IOL implantation, followed by GSL. Briefly, after the IOL was securely placed in the capsular bag, a cohesive ophthalmic viscosurgical device (OVD) was injected to deepen the anterior chamber and widen the iridocorneal angle. The patient's head was rotated approximately 30 to 45 degrees away from the surgeon, and the operating microscope was tilted toward the surgeon to optimize the visualization of the nasal angle. Under direct gonioscopic guidance using a surgical gonioprism, a blunt instrument (e.g., a cyclodialysis spatula or iris sweep) was used to apply gentle posterior and centripetal pressure to the peripheral iris.

Primary Outcomes

  • Intraocular pressure (1 month/3 months/6 months/12 months postoperatively)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-01
Completion: 2026-07-01
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 68 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University People's Hospital
Contact Information
Study Contact:
Zhiqiao Liang, Doctor
8613621338839
lzqliangzhiqiao@163.com
Zhiqiao Liang
8613621338839
lzqliangzhiqiao@163.com
Peking University People's Hospital
Interventions
  • Device: Kahook Dual Blade (KDB) goniotomy — he Kahook Dual Blade (KDB) is an ab interno device engineered to precisely excise a strip of diseased TM and the inner wall of Schlemm's canal.
  • Device: phacoemulsification with intraocular lens implantation combined with goniosynechialysis — patients underwent standard phacoemulsification with IOL implantation, followed by GSL. Briefly, after the IOL was securely placed in the capsular bag, a cohesive ophthalmic viscosurgical device (OVD) was injected to deepen the anterior chamber and widen the iridocorneal angle. The patient's head was rotated approximately 30 to 45 degrees away from the surgeon, and the operating microscope was tilted toward the surgeon to optimize the visualization of the nasal angle. Under direct gonioscopic guidance using a surgical gonioprism, a blunt instrument (e.g., a cyclodialysis spatula or iris sweep) was used to apply gentle posterior and centripetal pressure to the peripheral iris.
Study Locations (1 sites)
Peking University People's Hospital, Beijing, 100044 China
Eligibility Criteria
Inclusion Criteria: * (1) age ≥ 40 years; (2) a confirmed diagnosis of CPACG, defined as the presence of peripheral anterior synechiae (PAS) extending ≥ 180° on indentation gonioscopy, accompanied by glaucomatous optic neuropathy and corresponding visual field defects; (3) a visually significant cataract that impaired daily activities and necessitated phacoemulsification; and (4) inadequately controlled intraocular pressure (IOP), defined as an IOP \> 21 mmHg despite maximally tolerated anti-glaucoma medications, or an IOP ≤ 21 mmHg dependent on the continuous use of two or more topical medications. Exclusion Criteria: * (1) any form of secondary angle-closure glaucoma (e.g., neovascular, uveitic, or lens-induced glaucoma); (2) a history of prior intraocular surgery or incisional glaucoma procedures, although eyes with a previous uncomplicated laser peripheral iridotomy (LPI) were permitted; (3) concurrent severe ocular pathologies that could profoundly limit visual prognosis or confound functional assessments (e.g., severe diabetic retinopathy, advanced age-related macular degeneration, or optic atrophy of non-glaucomatous origin); (4) a central corneal endothelial cell density of \< 1500 cells/mm² to ensure the safety of the planned anterior chamber interventions; and (5) any severe systemic conditions precluding surgical tolerance or adherence to the 1-year follow-up protocol.
Conditions Glaucoma, Ocular Hypertension
Phase PHASE1, PHASE2
Enrollment 42
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma or ocular hypertension and requiring cataract surgery. The study is conducted in two stages. The first stage (Stage 1/Phase 1) is intended to study the safety of 3 different doses of the study medication (called TimoD implant). The second stage (Stage 2/Phase 2) of the study is intended to study in greater detail the efficacy and safety of the 3 doses of the TimoD implant in comparison to a standard approved medication, timolol eye drops for 3 years.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Drug: TimoD implant — Consists of 1 TimoD implant administration in the study eye.
  • Device: Injector system — This is a CE-marked injector intended for intraocular lens (IOL) delivery. In this study, the injector is used as an"intraocular implant injection system" outside of its scope of intended use.
  • Drug: Timolol eye drops 0.5% — Timolol eye drops will be self-admnistered twice daily in the study eye approximately 12 hours apart throughout the study

Primary Outcomes

  • Stage 1: Number (%) of participants experiencing adverse events (From Screening (up to Day -41) to end of stage 1 (Month 13))
  • Stage 1: Number (%) of participants experiencing adverse events of special interest (AESI) (From Screening (up to Day -41) to end of stage 1 (Month 13))
  • Stage 2: Proportion of responders defined as an IOP decrease of 20% or more between baseline and Month 3 (8 AM IOP) (Month 3)
  • Stage 2: Proportion of time-matched responders defined as an IOP decrease of 20% or more between baseline and Month 3 (8 AM and 10 AM) (Month 3)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-06-12
Completion: 2027-01
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: EyeD Pharma
Contact Information
Study Contact:
EyeD Pharma
+3242299000
dpo@eyedpharma.com
Interventions
  • Drug: TimoD implant — Consists of 1 TimoD implant administration in the study eye.
  • Device: Injector system — This is a CE-marked injector intended for intraocular lens (IOL) delivery. In this study, the injector is used as an"intraocular implant injection system" outside of its scope of intended use.
  • Drug: Timolol eye drops 0.5% — Timolol eye drops will be self-admnistered twice daily in the study eye approximately 12 hours apart throughout the study
Study Locations (1 sites)
Panama Eye Center, Panama City, Panama
Eligibility Criteria
Inclusion Criteria: * Capable of giving signed informed consent. * In good general and mental health without ongoing clinically significant abnormalities in medical history. * Open-angle glaucoma or ocular hypertension and age-related cataract eligible for intra-capsular IOL placement. * Successful, uncomplicated cataract surgery Exclusion Criteria: * Subjects with a history of hypersensitivity or contraindications to β- blockers. * Participants using any systemic or topical drug known to interfere with visual performance, pupil dilation, or iris structure * Significant risks caused by washout of ocular hypotensive medications. * Clinically significant ocular pathology other than OHT, glaucoma and cataract.
Conditions Breast Cancer, Lung Cancer, Colorectal C...
Phase Not Applicable
Enrollment 10000
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient. Certain drugs are now being developed that target specific molecules in the body that are believed to be part of the disease. Biomarkers are specific characteristics of the cancer that may help provide prognostic information (e.g. how well patients will be regardless of the treatments given) or help predict sensitivity or resistance to a specific treatment. The study will collect archival tumor samples (previously collected biopsy or surgical tumor samples) to provide biomarker data about a patient's cancer, which may help their physicians to identify which clinical trials of new drug treatments may be most appropriate for the patient in the future and may also guide the use of approved treatments that may potentially benefit the patient. Another goal of this study is to develop a province-wide registry of targeted gene sequencing testing results that will be made available to cancer researchers. Additional tumour tissue and blood samples collected from all study participants will also be stored in a biobank at the Ontario Institute for Cancer Research for future research. The study will also look at linking data from this study to other health care databases to further collect information about the health care the patients received, including medical tests, clinic visits, or procedures both before and after participating in this study. Having more information about patient health to relate to the DNA sequences may provide new insights into cancer and its treatment.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Number of patients included in a province-wide registry of NGS panel-based testing results (5 years)
  • Change in use of NGS panel-based testing in Ontario clinical genetic testing laboratories (5 years)
  • Number of patients included in province-wide repository of genomically-characterized tumour tissue and blood samples and their utilization rates for future research (5 years)
  • Change in rates of genomics based clinical research in Ontario (5 years)
  • Utilization rates of province-wide genomically-characterized and clinically-annotated patient base in enrollment into specific research initiatives (5 years)
  • Utilization rates of molecular profiling information provided to treating physicians in guiding future treatment decisions (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2016-08
Completion: 2027-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Health Network, Toronto
Collaborators: Princess Margaret Hospital, Canada
Principal Investigators:
  • Philippe Bedard, MD (PRINCIPAL_INVESTIGATOR) - Princess Margaret Hospital, Canada
  • Lillian Siu, MD (PRINCIPAL_INVESTIGATOR) - Princess Margaret Hospital, Canada
Contact Information
Study Contact:
Samanta Del Rossi
416-946-4501
samanta.delrossi@uhn.ca
Han (Jenny) Zhang
613-737-7700
hanzhang@ohri.ca
The Ottawa Hospital Cancer Centre
Kendra Christink
613-737-7700
kchristink@toh.ca
The Ottawa Hospital Cancer Centre
Interventions
N/A
Study Locations (7 sites)
Juravinski Cancer Centre, Hamilton, Ontario Canada
Kingston General Hospital, Kingston, Ontario Canada
London Health Sciences Centre, London, Ontario Canada
The Ottawa Hospital Cancer Centre, Ottawa, Ontario Canada
Princess Margaret Hospital, Toronto, Ontario M5G 2M9 Canada
Mount Sinai Hospital, Toronto, Ontario Canada
Sunnybrook Health Sciences Centre, Toronto, Ontario Canada
Eligibility Criteria
Inclusion Criteria: 1. Patients with histological confirmation of advanced solid tumor malignancies who are candidates for systemic therapy. 2. All patients must have sufficient FFPE archived tumor tissue for molecular profiling. 3. Patient must be ≥ 18 years old. 4. Patient's ECOG performance status equal to 0 or 1. 5. All patients must have a life expectancy of \> 6 months. 6. All patients must have adequate organ functions. 7. All patients must have signed and dated an informed consent form. Exclusion Criteria: 1\. Patients must not have received more than 2 lines of prior cytotoxic therapy for their recurrent/metastatic disease, with the exception of Phase I trial candidates who will not be excluded if more than 2 lines of prior cytotoxic therapy have been received.
Conditions Pancreatic Cancer, Thyroid Cancer, Lung ...
Phase Not Applicable
Enrollment 999999
Locations 42 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Development and Implementation of a Web-based Cancer Collaborative Registry (86 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2013-11-01
Completion: 2099-12
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: true
Enrollment: 999999 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Nebraska
Principal Investigators:
  • Kurt Fisher, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of Nebraska
Contact Information
Study Contact:
Artem Pachikov
402-559-0568
artem.pachikov@unmc.edu
Roseann Johnson
303-765-6840
roseann.johnson@adventhealth.com
Advent Health
Mohammed Salhab, MD
Advent Health
Interventions
N/A
Study Locations (42 sites)
Advent Health, Greenwood Village, Colorado 80111 United States
Hartford HealthCare Cancer Institute at Manchester Medical Hospital, Manchester, Connecticut 06040 United States
Florida Hospital Memorial Medical Center, Daytona Beach, Florida 32117 United States
Florida Hospital DeLand, DeLand, Florida 32720 United States
Florida Hospital FISH, Orange City, Florida 32763 United States
Florida Hospital Flagler, Palm Coast, Florida 32164 United States
Tallahassee Memorial Hospital, Tallahassee, Florida 32308 United States
Rush-Copley Cancer Care Center, Aurora, Illinois 60504 United States
Rush-Copley Healthcare Center, Yorkville, Illinois 60560 United States
Parkview Research Center, Fort Wayne, Indiana 46845 United States
Eligibility Criteria
Inclusion Criteria * Diagnosis/history of cancer * Risk for developing cancer or suspicious clinical findings * No history of cancer (normal control registry) * Able to provide informed consent * 19 years of age or older * English or Spanish speaking individuals Exclusion Criteria * Unable to provide informed consent because of cognitive impairment * Non-English or non-Spanish speaking individuals
Conditions Metastasis, Metastatic Breast Cancer, Me...
Phase Not Applicable
Enrollment 2000
Locations 21 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

Metastases represent the most threatening challenge in cancer. One of the management strategies for patients with Oligometastatic Cancer (OC) is Stereotactic ABlative Radiotherapy (SABR). However, there are few studies, and there is no defined clinical standard, nor are the radiobiological mechanisms that contribute to treatment response well understood. The focus should be on generating evidence to guide the personalization of radiotherapy beyond solely technological and anatomical precision. This could be achieved by recollecting clinical and biological data from patients that undergo this treatment and analyzing them to ultimately predict, with the help of artificial intelligence, which patients will be the most beneficiary and improve their survival rate.

Design

Study type: Observational Observational model: Case Control Time perspective: Other

Interventions / Regimen

  • Diagnostic Test: To propose a diagnostic test to determine the viability of Stereotactic ABlative Radiotherapy (SABR). — Analyze clinical data, medical images and molecular circulating features to propose which variables serve to select the patients that will achieve complete response after SABR.
  • Diagnostic Test: To propose a diagnostic test to determine the effectiveness of SABR. — Collect blood samples at five different time points before and after treatment and analyze circulating tumoral DNA, medical images, and metabolites to monitor the effect of SABR and its effectiveness.
  • Diagnostic Test: To propose a diagnostic test for Oligometastatic Cancer (OC). — Analyze circulating tumoral DNA and metabolites from blood samples in search of the profile of OC.

Primary Outcomes

  • Radiological rate (3 months after treatment)
  • Progression-Free Survival (5 years after treatment)
  • SABR toxicities (5 years after treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-12-01
Completion: 2037-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut Investigacio Sanitaria Pere Virgili
Collaborators: Hospital Ruber Internacional, Hospital Universitario Rey Juan Carlos, Quirón Madrid University Hospital, Hospital de La Luz, Institut Català d'Oncologia, Hospital Arnau de Vilanova, Hospital Universitari Sant Joan de Reus, Hospital Universitario Virgen Macarena, Hospital Universitario Reina Sofia de Cordoba, Hospital General Universitario de Valencia, Hospital Clínico Universitario de Valencia, Complejo Hospitalario Universitario de Albacete, Hospital de Terrassa, Hospital Universitario Ramon y Cajal, Hospital del Mar, Hospital Provincial de Castellon, Hospital de la Santa creu i Sant Pau - Barcelona, HM Sanchinarro University Hospital, Hospital Miguel Servet, University Hospital Virgen de las Nieves, Hospital Vall d'Hebron
Principal Investigators:
  • Meritxell Arenas, PhD. (STUDY_DIRECTOR) - Universitat Rovira i Virgili, Hospital Universitari Sant Joan de Reus
Contact Information
Study Contact:
Jorge Joven, Prof.
+34977310300
jorge.joven@urv.cat
Meritxell Arenas, PhD.
meritxell.arenas@urv.cat
Sebastià Sabater
Complejo Hospitalario Universitario Albacete
Interventions
  • Diagnostic Test: To propose a diagnostic test to determine the viability of Stereotactic ABlative Radiotherapy (SABR). — Analyze clinical data, medical images and molecular circulating features to propose which variables serve to select the patients that will achieve complete response after SABR.
  • Diagnostic Test: To propose a diagnostic test to determine the effectiveness of SABR. — Collect blood samples at five different time points before and after treatment and analyze circulating tumoral DNA, medical images, and metabolites to monitor the effect of SABR and its effectiveness.
  • Diagnostic Test: To propose a diagnostic test for Oligometastatic Cancer (OC). — Analyze circulating tumoral DNA and metabolites from blood samples in search of the profile of OC.
Study Locations (21 sites)
Complejo Hospitalario Universitario Albacete, Albacete, Albacete Spain
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Barcelona, Barcelona Spain
Hospital Universitari Vall d'Hebron, Barcelona, Barcelona Spain
Institut Català d'Oncologia, Barcelona, Barcelona Spain
Hospital Universitario Virgen de las Nieves, Granada, Granada Spain
Hospital Universitari Arnau de Vilanova, Lleida, Lleida Spain
Hospital de La Luz, Madrid, Madrid Spain
Hospital Ruber Internacional, Madrid, Madrid Spain
Hospital Universitario HM Sanchinarro, Madrid, Madrid Spain
Hospital Universitario Quirónsalud, Madrid, Madrid Spain
Eligibility Criteria
Inclusion Criteria: * Histologic confirmation of primary tumor: breast, prostate, lung, colorectal. * 18 years old or older. * Up to five metastases located in the bone, lung, node, liver or brain. * Eastern Cooperative Oncology Group (ECOG) Performance Status Scale 0 or 1. Exclusion Criteria: * Non-melanoma skin cancer. * Previous radiotherapy in the same anatomic location. * Presence of vascular collagen disease. * Pregnancy or lactation at the time of inclusion.
Conditions Lymphedema Arm
Phase NA
Enrollment 136
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the effectiveness of the Lymphovenous Bypass (LVB) procedure compared to physiotherapy alone as secondary prevention of lymphedema in breast cancer patients undergoing axillary lymph node dissection.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Procedure: Lymphovenous bypass (LVB) — The Lymphovenous Bypass (LVB) procedure in this study is a microsurgical supermicrosurgery-based intervention specifically designed for the secondary prevention of breast cancer-related lymphedema following axillary lymph node dissection.

Primary Outcomes

  • BCRL improvement rate (24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-18
Completion: 2028-03-21
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 136 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dharmais National Cancer Center Hospital
Principal Investigators:
  • Bayu Brahma, MD, PhD (PRINCIPAL_INVESTIGATOR) - Dharmais Cancer Hospital - National Cancer Center
Contact Information
Study Contact:
Adhitya B Perdana, MEpi
+62 85692445029
adhityabayu@dharmais.co.id
Natarini Setianingsih
+62 5681570
dharmais@dharmais.co.id
Dharmais National Cancer Center
Interventions
  • Procedure: Lymphovenous bypass (LVB) — The Lymphovenous Bypass (LVB) procedure in this study is a microsurgical supermicrosurgery-based intervention specifically designed for the secondary prevention of breast cancer-related lymphedema following axillary lymph node dissection.
Study Locations (1 sites)
Dharmais National Cancer Center, Jakarta, Jakarta Special Capital Region 11420 Indonesia
Eligibility Criteria
Inclusion Criteria: * Breast cancer patients aged ≥ 18 years with an ECOG score \> 1 * Breast cancer patients with post-axillary lymph node dissection diagnosed with stage 0 and I lymphedema. * Those who have never undergone lymphedema physiotherapy. Exclusion Criteria: * Patients with dermal backflow before axillary lymph node dissection (ALND). * Patients with breast cancer lymphedema who are unable to undergo a 24-month follow-up at Dharmais Cancer Hospital. * Patients with iodine allergy, severe asthma, decreased kidney function, pregnancy, or breastfeeding.
Conditions Metastatic Breast Cancer
Phase NA
Enrollment 12
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

Triple-negative breast cancer (TNBC) is a particularly aggressive type of breast cancer that is difficult to treat. Unlike other forms of breast cancer, TNBC tends to relapse earlier and spread more quickly to other parts of the body. Unfortunately, patients with TNBC have a lower survival rate, often less than five years after diagnosis. This highlights the urgent need for better treatments for TNBC. One of the main challenges in treating TNBC is that it lacks certain receptors that other breast cancers have. These receptors are usually targeted by specific therapies, making TNBC harder to treat with targeted approaches. Currently, a type of imaging called \[18F\]FDG PET/CT is the most accurate method for detecting breast cancer and its spread. However, with the rise of personalized medicine, there is a growing interest in molecular targeted approaches. These methods aim to provide highly specific diagnostics and treatments based on the unique characteristics of each patient's cancer. One promising target for these new approaches is a receptor called CXCR4. CXCR4 is found on the surface of many cells and is involved in various processes in the body. It is often overexpressed in different types of cancer, including breast cancer. Research has shown that CXCR4 levels are higher in metastatic sites (where cancer has spread) compared to primary tumors. CXCR4 is not only present in cancer cells but also in immune cells within the tumor environment. In invasive breast cancer, CXCR4 plays a crucial role in tumor migration, invasiveness, metastasis, and proliferation. A clinical study evaluated 18 breast cancer patients using a new imaging method called \[68Ga\]Ga-PentixaFor PET/CT or PET/MR. They found that this method showed higher uptake in breast cancer cases with poorer prognosis compared to the traditional \[18F\]FDG PET/CT. Higher CXCR4 expression is particularly seen in TNBC compared to other breast cancer subtypes. The goal of the study is to assess how \[68Ga\]Ga-PentixaFor is distributed in the body using PET/CT imaging. This will help demonstrate the potential of CXCR4 as a promising target for new treatments. If successful, \[68Ga\]Ga-PentixaFor PET/CT could become a valuable tool for identifying patients who might benefit from treatments using \[177Lu\]/\[90Y\] PentixaTher.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: [68Ga]Ga-PentixaFor PET/CT — \[68Ga\]Ga-PentixaFor PET-CT is performed after patient inclusion. The patient is treated as per standard of care until disease progression. Then another \[68Ga\]Ga-PentixaFor PET-CT is performed.

Primary Outcomes

  • To assess the concordance for tumour lesion detection with [68Ga]Ga-PentixaFor PET/CT and [18F]FDG PET/CT based on a lesion-by-lesion basis analysis performed at patient inclusion (1 day)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-05
Completion: 2030-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 12 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut Cancerologie de l'Ouest
Principal Investigators:
  • CAROLINE ROUSSEAU, MD, PhD (PRINCIPAL_INVESTIGATOR) - Institut de Cancérologie de l'Ouest (ICO)
Contact Information
Study Contact:
CAROLINE ROUSSEAU, MD, PhD
+33 2 40 67 99 31
Caroline.Rousseau@ico.unicancer.fr
NADIA ALLAM, PhD
+33 2 40 67 98 26
nadia.allam@ico.unicancer.fr
Caroline ROUSSEAU, MD, PhD
+33240679931
caroline.rousseau@ico.unicancer.fr
Institut de cancerologie de l'Ouest
Interventions
  • Diagnostic Test: [68Ga]Ga-PentixaFor PET/CT — \[68Ga\]Ga-PentixaFor PET-CT is performed after patient inclusion. The patient is treated as per standard of care until disease progression. Then another \[68Ga\]Ga-PentixaFor PET-CT is performed.
Study Locations (1 sites)
Institut de cancerologie de l'Ouest, Saint-Herblain, 44805 France
Eligibility Criteria
Inclusion Criteria: 1. Written informed consent obtained from the patient prior to performing any protocol-related procedures, including screening evaluations. 2. Female or male, Age ≥ 18 years at time of study entry. 3. Primitive triple negative breast cancer proven histologically, defined according to the following criteria: * Estrogen receptors \<10%. * And progesterone receptors \<10%. * And HER2 not amplified or not overexpressed. 4. Recurrence metastatic Breast Cancer or De Novo metastatic Breast Cancer documented by \[18F\]FDG PET/CT ± conventional imaging with at least one measurable metastasis according to PERCIST and/or RECIST. 5. ECOG performance status \< 2. 6. Negative serum/urine pregnancy test prior to \[68Ga\]Ga-PentixaFor administration for female patient of childbearing potential\*. 7. Consent to use a contraception method for at least 3 months after each administration of \[68Ga\]Ga-PentixaFor (as defined in Appendix 7 and according to local guidelines). 8. Adequate Organ function confirmed by laboratory tests results allowing for safe administration of \[68Ga\]Ga- PentixaFor: Hematologic function: Absolute Neutrophil Count (ANC) of ≥ 1.5 x 109 /L, platelet count of ≥ 100 x 109 /L, and hemoglobin of ≥ 9 g/dL). Hepatic function: AST and ALT ≤ 3 x ULN (≤ 5 x ULN if liver metastases). 9. Renal function: Estimated Glomerular Filtration Rate (eGFR) ≥ 50 mL/min/1.73m², as calculated using the CKD-EPI or MDRD equation.Life expectancy at least 3 months. 10. Patient has valid health insurance. 11. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up. * Note: a female participant of childbearing potential is a woman who is not permanently sterilized or not postmenopausal (postmenopausal is defined as 12 months with no menses without an alternative medical cause). Exclusion Criteria: 1. History of another primary malignancy within the last 3 years before study entry except for basal cell carcinoma. 2. Impossibility to hold lying motionless at least 1 hour, or known claustrophobia. 3. Serious non-malignant disease (e.g. psychiatric, infectious, autoimmune or metabolic), that may interfere with the objectives of the study or with the safety or compliance of the subject, as judged by the investigator. 4. Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study. 5. Pregnant, likely to be pregnant or breastfeeding woman. 6. Blood glucose \> 12mmol/L. 7. Renal insufficiency with GFR ≤ 45 mL/min/ 1.73 m². 8. Known hypersensitivity to any active pharmaceutical agent or constituent of the \[68Ga\]Ga-PentixaFor and/or \[18F\]FDG product. 9. Body weight of less than 48 kg. 10. Persons deprived of their liberty, under a measure of safeguard of justice, under guardianship or placed under the authority of a guardian. 11. Disorder precluding understanding of trial information or informed consent.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 15000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

The current observational study aims to perform the sentinel lymph node in breast cancer in the usual way with technetium 99 and add a second tracer, indocyanine green. The objective is to evaluate the detection rate of the lymph node with indocyanine green compared to the usual technique.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Application of green indocyanine colorant — The day of the surgery 1 ml of green indocyanine colorant will be applicated periareolar. After 5 minutes the lymph node will be detected and extracted
  • Drug: Technetium99 — Application of a periareolar injectionof TEchnetium 99 in order to detect the axillary lymph node

Primary Outcomes

  • Number of Sentinel lymph node detected. Scale of numbers (patients included from 1 January of 2024 til January 1 2029)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-01-01
Completion: 2029-01-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 15000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Omphis Foundation
Principal Investigators:
  • Sandra Lopez gordo (STUDY_DIRECTOR) - 46873584K
Contact Information
Study Contact:
Sandra Lopez gordo
0034660284047
sandra.lopezgordo@gmail.com
Sandra Lopez gordo
660284047
sandra.lopezgordo@gmail.com
Sandra Lopez gordo
660284047
sandra.lopezgordo@gmail.com
Sandra Lopez Gordo
Interventions
  • Other: Application of green indocyanine colorant — The day of the surgery 1 ml of green indocyanine colorant will be applicated periareolar. After 5 minutes the lymph node will be detected and extracted
  • Drug: Technetium99 — Application of a periareolar injectionof TEchnetium 99 in order to detect the axillary lymph node
Study Locations (1 sites)
Sandra Lopez Gordo, Cerdanyola del Vallès, Barcelona 08290 Spain
Eligibility Criteria
Inclusion Criteria: * Patients \>18 years of age with breast cancer who are candidates for sentinel lymph node detection will be included. * N0 patients or patients who have undergone target axillary detection with good response Exclusion Criteria: * Lymphadenectomy